Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
Verywell Health on MSN2d
A New FDA-Approved Antibiotic May Help Women With Recurring UTIsFact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new antibiotic to treat urinary ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
Everyday Health on MSN7d
New UTI Antibiotic Is the First Approved by the FDA in Nearly 30 YearsThis antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The ...
The FDA has approved GSK’s gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged ...
The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...
The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback